'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study


REUTERS: More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday. Of 18 patients who received a therapeutic dose of bb2121, all but one responded to the treatment, a 94 percent response rate, while 56 percent remained in remission with a median follow-up of 40 weeks after treatment.



from Biotech News